Transgenomic announced this week that it has signed an agreement with Amgen to develop an IVD test to identify NRAS and KRAS mutated patients with advanced colorectal cancer using its RAScan kits.

The test is already available as an LDT through Transgenomic's CLIA lab and should be available soon in Europe under a CE mark. The company is also planning on offering a research-use only kit version of the test in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A company hopes to capture the genetic diversity in India to power tailored therapeutics, BBC News reports.

The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.

Researchers tie variants in seven genes to insomnia risk, Live Science reports.

In PLOS this week: locus near OAS1 linked to Sjogren's syndrome, rotavirus reassortment events uncovered by sequencing, and more.